Dizziness Clinical Trial
Official title:
Quantification of the Effect of the OtoBand, a Non-invasive Vestibular Masker, on Objective Measures of Vertigo and Dizziness
Verified date | November 2022 |
Source | Otolith Labs |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Vestibular disorders are among the most common causes of disability in society and affect over 50% of the population over the age of 65 and a significant percentage of the younger population. Vestibular disorders have a dramatic impact on daily life impacting work, relationships, and even activities of daily living.The OtoBand has shown promise and might be beneficial for treating or improving the course of recovery from vestibular disorders. This study seeks to quantify the effect of the study device, the OtoBand, on objective measures of dizziness and vertigo in patients with vestibular dysfunction. The study will be conducted at a single-site and will be a blinded, randomized, placebo-controlled design in which participants do not know if they are receiving bone conducted stimulation 1) at a therapeutic level or 2) at a non therapeutic level.
Status | Completed |
Enrollment | 28 |
Est. completion date | September 1, 2022 |
Est. primary completion date | August 9, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Vertigo that has been present for at least 90 days, constant or predictable with attacks at least twice a week. - Classified as having vertigo from one of the following vestibulogenic vertigo conditions: - Migraine Associated Vertigo, aka Vestibular Migraine - Chronic Unilateral Vestibulopathy in one of three forms: Persistent Postural-Perceptual Dizziness (aka 3PD), Vestibular Neuritis, Labyrinthitis - Score > 35 on Dizziness Handicap Inventory - Willingness to cease vestibular suppressants for 24h prior to study. Exclusion Criteria: - Vertigo that first presented within the last 90 days - Skull base surgery within the last 90 days - Any skull implant (cochlear implant, bone conduction implant, DBS) - Resolved vestibular dysfunction by the time of study appointment - History of head injury within the last 6 months or currently suffering the effects of a head injury - History of diagnosed untreated neuropsychiatric disorders (hypochondriasis, major depression, schizophrenia) - Prior documented neurodegenerative disorders of hearing and balance including: - Multiple sclerosis - Vestibular schwannoma - History of Cerebrovascular disorders - History of ear operation other than myringotomy (tube placement) - Vitreous detachment of the retina (floaters) in the previous 90 days - Presence of severe aphasia, and individuals who cannot provide informed consent |
Country | Name | City | State |
---|---|---|---|
United States | Dizzy and Vertigo Institute of Los Angeles | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Otolith Labs | Dizzy and Vertigo Institute of Los Angeles |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determine change in objective measures of vestibular symptoms, namely change in VOR Gain induced by the OtoBand. | We measure the Gain of the Vestibular Ocular Reflex (VOR) associated with sinusoidal harmonic accelerations (SHAs) at multiple frequencies of rotation. The mean Gain across all frequencies will be computed for each three experimental conditions (OtoBand/sham/no device). The quantifiable outcome will be the deviation from nominal values of the Gain as a function of experimental condition. | Within 60 minute trial period. | |
Primary | Determine change in objective measures of vestibular symptoms, namely change in VOR Phase induced by the OtoBand. | We measure the Phase of the Vestibular Ocular Reflex (VOR) associated with sinusoidal harmonic accelerations (SHAs) at multiple frequencies of rotation. The mean phase lag across all frequencies will be computed for each three experimental conditions (OtoBand/sham/no device). The quantifiable outcome will be the deviation from nominal values of the phase lag as a function of experimental condition. | Within 60 minute trial period. | |
Secondary | Participant's questionnaire as to which power level they believe were sham setting vs therapeutic setting | Compare participants' estimation of which device provided the most benefits, to the improvement in VOR gain measured during sinusoidal harmonic accelerations (SHAs). | Within 60 minute trial period. | |
Secondary | Measure whether Vestibular Migraine and Vestibulopathy patients experience higher benefits from a low vs high bone conduction levels as measured by outcomes of objective tests (SHAs and spontaneous nystagmus) | Measure statistically significant changes in VOR gain as measured from Sinusoidal Harmonic Accelerations (SHAs) and spontaneous nystagmus, as a function of the OtoBand's power level and as a function of the participant's condition (vestibular migraine vs vestibulopathy) | Within 60 minute trial period. | |
Secondary | Determine change in objective measures of vestibular symptoms, namely change in residual nystagmus following SHAs, as a function of experimental condition. | Following sinusoidal harmonic accelerations (SHAs) in the rotary chair, we measure residual eye movements (nystagmus) for one minute at rest. The amplitude and frequency of these eye movements will be computed for each three experimental conditions (OtoBand/sham/no device). The quantifiable outcome will be the deviation from nominal values of the nystagmus as a function of experimental condition. | Within 60 minute trial period. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Completed |
NCT05427097 -
Thermal Energy in the Treatment of Cervicogenic Dizziness
|
N/A | |
Completed |
NCT02299128 -
Effectiveness of Early Physical Therapy Intervention for Patients With Dizziness After a Sports-Related Concussion
|
N/A | |
Completed |
NCT02733549 -
Is The Sudden Onset of Dizziness A Symptom of Acute Liver Dysfunction?
|
N/A | |
Completed |
NCT05812209 -
Stellate Ganglion Block to Treat Long COVID 19 Case Series
|
||
Not yet recruiting |
NCT03973658 -
Dizziness Among First Time Users of Hearing Aids
|
||
Completed |
NCT03182868 -
Vestibular Testing: Consistency and Effects Over Time
|
N/A | |
Completed |
NCT02938221 -
Telemedical Examination of a Three-Component Oculomotor Testing Battery
|
N/A | |
Active, not recruiting |
NCT02655575 -
Assessment and Treatment of Patients With Long-term Dizziness in Primary Care
|
N/A | |
Completed |
NCT02772042 -
Traction Manipulation of Upper Cervical Spine on Cervicogenic Dizziness
|
N/A | |
Completed |
NCT00732797 -
A Trial of Booklet Based Self Management of Dizziness
|
N/A | |
Not yet recruiting |
NCT06010550 -
Validating a Clinical Decision Support Tool for Stratifying Stroke Risk for Dizziness/Vertigo
|
||
Recruiting |
NCT03618199 -
Efficacy of a Transcranial Vibrating System for Minimizing Dizziness During Caloric Testing
|
N/A | |
Completed |
NCT03330262 -
Head-Mounted Vibrotactile Prosthesis for Patients With Chronic Postural Instability
|
N/A | |
Completed |
NCT02344446 -
Physical Therapy Intervention for Extended Physical Symptoms After a Sports-related Concussion
|
N/A | |
Withdrawn |
NCT00732108 -
Is Topiramate Effective in Treating Dizziness in Patient's With Migraine-Associated Dizziness
|
N/A | |
Active, not recruiting |
NCT05122663 -
Emergency Department Vestibular Rehabilitation Therapy for Dizziness and Vertigo
|
||
Recruiting |
NCT05634902 -
Implementation of Evidence-Based Practice for Dizziness
|
N/A | |
Completed |
NCT02640599 -
Stationary Bike Study
|
N/A | |
Enrolling by invitation |
NCT05990023 -
The Effect of Computerized Vestibular Function Assessment and Training System Combined With Cognitive/Motor Dual-task
|
N/A |